Are you getting the best rate from your broker?
Compare your broker's rates now to find out if you can save money

Choose your broker below
Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you
Mutualfunds logo

VGHCX Vanguard Health Care Inv

  • Fund
  • VGHCX
  • Price as of: Aug 17, 2018
  • $219.65
  • + $1.00
  • + 0.46%
  • Category
  • Health & Biotech Equities

VGHCX - Profile

Vitals

  • YTD Return 6.9%
  • 3 Yr Annualized Return 4.1%
  • 5 Yr Annualized Return 13.8%
  • Net Assets $47.9 B
  • Holdings in Top 10 41.0%

52 WEEK LOW AND HIGH

$219.65
$192.97
$222.94

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.38%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 11.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

STANDARD (TAXABLE)

$0

IRA

$3,000

Investment Themes

CATEGORY

Health & Biotech Equities
  • Fund Type Open End Mutual Fund
  • Investment Style Health

Distributions

  • YTD Total Return 6.9%
  • 3 Yr Annualized Total Return 4.1%
  • 5 Yr Annualized Total Return 13.8%
  • Capital Gain Distribution Frequency None
  • Net Income Ratio 1.02%
DIVIDENDS
  • Dividend Yield N/A
  • Dividend Distribution Frequency None

Fund Details

  • Legal Name Vanguard Health Care Fund
  • Fund Family Name Vanguard
  • Inception Date May 23, 1984
  • Shares Outstanding N/A
  • Share Class Inv
  • Currency USD
  • Domiciled Country United States
  • Manager Jean M. Hynes

Fund Description

The Vanguard Health Care Fund Investor Shares (VGHCX) offers investors low-cost exposure to domestic and foreign companies involved in various aspects of the health care industry, such as pharmaceutical firms, medical supply companies and research firms. Given its narrow focus, VGHCX is better suited for those investors looking to add complementary exposure to an already diversified portfolio.

The actively managed fund seeks to maintain exposure across five primary subsectors: health services, medical products, specialty pharmaceuticals, major pharmaceuticals and international markets. Fundamental research focuses on companies with high-quality balance sheets, strong management, and the potential for new products that will lead to above-average growth in revenue and earnings. VGHCX is managed by Wellington Management Company.

VGHCX - Performance

Return Ranking - Trailing

Period VGHCX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD 6.9% -89.5% 24.1% 78.57% 4
1 Yr 8.4% -14.8% 47.9% 85.59% 5
3 Yr 4.1% * -7.5% 17.2% 46.30% 3
5 Yr 13.8% * 7.4% 20.8% 46.73% 3
10 Yr 13.1% * 6.1% 18.5% 50.49% 3

* Annualized


Return Ranking - Calendar

Period VGHCX Return Category Return Low Category Return High Rank in Category (%) Quintile
2017 11.2% -19.5% 43.9% 70.00% 4
2016 -16.2% -29.8% 14.5% 58.18% 3
2015 4.1% -20.4% 33.7% 16.36% 1
2014 13.1% -5.8% 48.1% 61.82% 4
2013 30.6% -3.1% 65.2% 63.30% 4

Total Return Ranking - Trailing

Period VGHCX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD 6.9% -89.5% 24.1% 79.28% 4
1 Yr 8.4% -18.3% 47.9% 72.73% 4
3 Yr 4.1% * -14.2% 17.1% 43.52% 3
5 Yr 13.8% * 6.7% 20.8% 45.79% 3
10 Yr 13.1% * 6.1% 18.5% 47.57% 3

* Annualized


Total Return Ranking - Calendar

Period VGHCX Return Category Return Low Category Return High Rank in Category (%) Quintile
2017 11.2% -19.5% 43.9% 70.64% 4
2016 -14.3% -25.1% 39.1% 55.05% 3
2015 14.1% -16.6% 100.0% 17.43% 1
2014 38.1% -5.8% 79.8% 32.11% 2
2013 78.7% 0.0% 398.7% 41.67% 3

NAV & Total Return History

VGHCX - Holdings

Filings data as of: Jun 30, 2018

Concentration Analysis

VGHCX Category Low Category High VGHCX % Rank Quintile
Net Assets 47.9 B 17.2 M 47.9 B 0.89% 1
Number of Holdings 100 28 378 11.61% 2
Net Assets in Top 10 18.6 B 9.84 M 18.6 B 0.89% 1
Weighting of Top 10 41.0% 22.0% 72.8% 16.07% 2

Top 10 Holdings

  1. Allergan PLC 5.11%
  2. Merck & Co Inc 3.09%
  3. Bristol-Myers Squibb Company 6.18%
  4. UnitedHealth Group Inc 6.03%
  5. AstraZeneca PLC 5.38%
  6. Eli Lilly and Co 4.56%
  7. Medtronic PLC 2.75%
  8. Vertex Pharmaceuticals Inc 2.76%
  9. Eisai Co Ltd 2.60%
  10. Boston Scientific Corp 2.53%

Asset Allocation

Weighting Category Low Category High VGHCX % Rank Quintile
Stocks
96.70% 91.77% 100.47% 24.11% 4
Other
2.16% -2.40% 5.18% 2.68% 1
Cash
1.15% 0.00% 7.04% 21.43% 4
Preferred Stocks
0.00% 0.00% 2.19% 10.71% 5
Convertible Bonds
0.00% 0.00% 0.26% 3.57% 5
Bonds
0.00% 0.00% 4.69% 3.57% 5

Stock Sector Breakdown

Weighting Category Low Category High VGHCX % Rank Quintile
Healthcare
92.82% 11.13% 99.44% 31.25% 4
Technology
2.48% 0.00% 66.03% 9.82% 2
Consumer Defense
1.07% 0.00% 1.31% 1.79% 1
Real Estate
0.32% 0.00% 1.12% 1.79% 1
Utilities
0.00% 0.00% 0.26% 1.79% 5
Industrials
0.00% 0.00% 8.36% 8.93% 5
Financial Services
0.00% 0.00% 6.65% 8.04% 5
Energy
0.00% 0.00% 0.08% 1.79% 5
Communication Services
0.00% 0.00% 0.00% 0.89% 5
Consumer Cyclical
0.00% 0.00% 8.32% 10.71% 5
Basic Materials
0.00% 0.00% 0.52% 2.68% 5

Stock Geographic Breakdown

Weighting Category Low Category High VGHCX % Rank Quintile
US
72.23% 65.77% 99.57% 33.93% 5
Non US
24.47% 0.00% 33.78% 4.46% 1

VGHCX - Expenses

Operational Fees

VGHCX Fees (% of AUM) Category Low Category High Rank in Category (%) Quintile
Expense Ratio 0.38% 0.10% 4.31% 67.86% 1
Management Fee 0.35% 0.09% 1.25% 18.75% 1
12b-1 Fee N/A 0.00% 1.00% N/A N/A
Administrative Fee N/A 0.01% 0.40% N/A N/A

Sales Fees

VGHCX Fees (% of AUM) Category Low Category High VGHCX Rank Quintile
Front Load N/A 2.50% 5.75% N/A N/A
Deferred Load N/A 1.00% 5.00% N/A N/A

Trading Fees

VGHCX Fees (% of AUM) Category Low Category High VGHCX Rank Quintile
Max Redemption Fee N/A 0.75% 2.00% N/A N/A

Turnover Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

VGHCX Fees (% of AUM) Category Low Category High VGHCX Rank Quintile
Turnover 11.00% 0.00% 699.00% 30.36% 1

VGHCX - Distributions

Dividend Yield Analysis

VGHCX Category Low Category High VGHCX % Rank Quintile
Dividend Yield N/A 0.01% 0.94% N/A N/A

Dividend Distribution Analysis

VGHCX Category Low Category High Category Mode
Dividend Distribution Frequency None Annually Quarterly Annually

Dividend Payout History


Net Income Ratio Analysis

VGHCX Category Low Category High VGHCX % Rank Quintile
Net Income Ratio 1.02% -2.22% 1.46% 3.57% 1

Capital Gain Distribution Analysis

VGHCX Category Low Category High Capital Mode
Capital Gain Distribution Frequency None Annually Semi-Annually Annually

VGHCX - Managers

Jean M. Hynes

Manager

Start Date

May 29, 2008

Tenure

10.18

Tenure Rank

13.3%

Jean M. Hynes, CFA, Senior Vice President, Managing Partner, and Global Industry Analyst, is involved in portfolio management and securities analysis at Wellington Management. Jean holds a BA in economics from Wellesley College (1991). She joined Wellington Management upon her graduation. She holds the Chartered Financial Analyst designation, and is a member of the CFA Institute and the Boston Security Analysts Society.


Tenure Analysis

Category Low

0.0

Category High

20.9

Category Average

9.36

Category Mode

3.6